In VivoThis year has posed substantial challenges for global markets: a prolonged period of high interest rates, ongoing geopolitical instability, democratic uncertainty, and an unprecedented number of natio
Pink SheetA cluster of recent breakthrough therapy designation awards in liver disease highlight advances in the field ahead of the US Food and Drug Administration’s difficult, and now delayed, decision on the
ScripIn this edition of Scrip ’s M&A podcast, colleagues Joseph Haas, Kevin Grogan and Edwin Elmhirst highlight some of the companies they think are the most appealing takeout candidates for deep-pocketed
ScripThe shift in terminology from NASH to MASH seems to be taking hold judging by public statements from companies working in the space, as well as some of the market analysts commenting on developments i